{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:18:26Z","timestamp":1790716706034,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"publisher","award":["Ricerca di Ateneo"],"award-info":[{"award-number":["Ricerca di Ateneo"]}],"id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Netherlands Heart Foundation","award":["CVON DOSIS, grant 2014-40"],"award-info":[{"award-number":["CVON DOSIS, grant 2014-40"]}]},{"name":"Netherlands Heart Foundation","award":["CVON SHE-PREDICTS-HF, grant 2017-21"],"award-info":[{"award-number":["CVON SHE-PREDICTS-HF, grant 2017-21"]}]},{"name":"Netherlands Heart Foundation","award":["CVON RED-CVD, grant 2017-11"],"award-info":[{"award-number":["CVON RED-CVD, grant 2017-11"]}]},{"name":"Netherlands Organization for Scientific Research","award":["NWO VIDI, grant 917.13.350"],"award-info":[{"award-number":["NWO VIDI, grant 917.13.350"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10741-019-09820-2","type":"journal-article","created":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T11:02:31Z","timestamp":1561806151000},"page":"915-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens"],"prefix":"10.1007","volume":"24","author":[{"given":"Christian","family":"Cadeddu Dessalvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gimelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Nugara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-688X","authenticated-orcid":false,"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mercuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,29]]},"reference":[{"key":"9820_CR1","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"9820_CR2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35:893\u2013911","journal-title":"J Clin Oncol"},{"key":"9820_CR3","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.6004\/jnccn.2018.0078","volume":"16","author":"CS Denlinger","year":"2018","unstructured":"Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA (2018) Survivorship, Version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16:1216\u20131247. \nhttps:\/\/doi.org\/10.6004\/jnccn.2018.0078","journal-title":"J Natl Compr Cancer Netw"},{"issue":"45","key":"9820_CR4","doi-asserted-by":"crossref","first-page":"79289","DOI":"10.18632\/oncotarget.17808","volume":"8","author":"H-Y Wang","year":"2017","unstructured":"Wang H-Y, Yin B-B, Jia D-Y, Hou Y-L (2017) Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer. Oncotarget 8(45):79289\u201379297","journal-title":"Oncotarget"},{"key":"9820_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","volume":"9","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, Mercurio V, Monte I, Novo G, Parrella P, Pirozzi F, Pecoraro A, Spallarossa P, Zito C, Mercuro G, Pagliaro P, Tocchetti CG (2018) Antineoplastic drug-induced cardiotoxicity: a redox perspective. Front Physiol 9:167. \nhttps:\/\/doi.org\/10.3389\/fphys.2018.00167","journal-title":"Front Physiol"},{"key":"9820_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/annonc\/mdf118","volume":"13","author":"LC Kremer","year":"2002","unstructured":"Kremer LC, van Dalen EC, Offringa M, Vou\u02c6te PA (2002) Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 13:503\u2013512","journal-title":"Ann Oncol"},{"key":"9820_CR7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","volume":"34","author":"TM Suter","year":"2013","unstructured":"Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34:1102\u20131111","journal-title":"Eur Heart J"},{"key":"9820_CR8","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869\u20132879","journal-title":"Cancer"},{"key":"9820_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","volume":"20","author":"P Ameri","year":"2018","unstructured":"Ameri P, Canepa M et al (2018) Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 20:879\u2013887. \nhttps:\/\/doi.org\/10.1002\/ejhf.1165","journal-title":"Eur J Heart Fail"},{"key":"9820_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10741-016-9564-5","volume":"21","author":"D Mele","year":"2016","unstructured":"Mele D, Nardozza M, Spallarossa P, Frassoldati A, Tocchetti CG, Cadeddu C, Madonna R, Malag\u00f9 M, Ferrari R, Mercuro G (2016) Current views on anthracycline cardiotoxicity. Heart Fail Rev 21:621\u2013634","journal-title":"Heart Fail Rev"},{"key":"9820_CR11","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Pi\u00f1a IL, Volgman AS, American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research (2018) Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 137:e30\u2013e66. \nhttps:\/\/doi.org\/10.1161\/CIR.0000000000000556","journal-title":"Circulation"},{"key":"9820_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchf.2017.08.024","volume":"6","author":"B Kenigsberg","year":"2018","unstructured":"Kenigsberg B, Wellstein A, Barac A (2018) Left ventricular dysfunction in cancer treatment: is it relevant? JACC Heart Fail 6:87\u201395. \nhttps:\/\/doi.org\/10.1016\/j.jchf.2017.08.024","journal-title":"JACC Heart Fail"},{"key":"9820_CR13","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu04","volume":"25","author":"DSM Chan","year":"2014","unstructured":"Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901\u20131914. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdu04","journal-title":"Ann Oncol"},{"key":"9820_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.taap.2008.05.006","volume":"231","author":"MS Mitra","year":"2008","unstructured":"Mitra MS, Donthamsetty S, White B, Mehendale HM (2008) High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 231:413\u2013422","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"9820_CR15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215\u20131221. \nhttps:\/\/doi.org\/10.1200\/JCO.2002.20.5.1215","journal-title":"J Clin Oncol"},{"issue":"10","key":"9820_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","volume":"7","author":"MS Ewer","year":"2010","unstructured":"Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7(10):564\u2013575. \nhttps:\/\/doi.org\/10.1038\/nrcardio.2010.121","journal-title":"Nat Rev Cardiol"},{"issue":"25","key":"9820_CR17","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JGM, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25(25):3859\u20133865. \nhttps:\/\/doi.org\/10.1200\/JCO.2006.09.1611","journal-title":"J Clin Oncol"},{"issue":"18","key":"9820_CR18","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1089\/ars.2016.6930","volume":"30","author":"CG Tocchetti","year":"2019","unstructured":"Tocchetti CG, Cadeddu C, Di Lisi D, Femmin\u00f2 S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, Spallarossa P, Varricchi G, Zito C, Pagliaro P, Mercuro G (2019 Jun 20) From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview. Antioxid Redox Signal 30(18):2110\u20132153. \nhttps:\/\/doi.org\/10.1089\/ars.2016.6930","journal-title":"Antioxid Redox Signal"},{"issue":"Suppl 1","key":"9820_CR19","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.2459\/JCM.0000000000000381","volume":"17","author":"P Spallarossa","year":"2016","unstructured":"Spallarossa P, Maurea N, Cadeddu C et al (2016) A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown) 17(Suppl 1):S84\u2013S92","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"20","key":"9820_CR20","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gon\u00e7alves Brand\u00e3o SM, VOC R, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, MSM F, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 71(20):2281\u20132290. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2018.02.049","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"9820_CR21","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.783","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017 Mar 10) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35(8):870\u2013877. \nhttps:\/\/doi.org\/10.1200\/JCO.2016.68.783","journal-title":"J Clin Oncol"},{"key":"9820_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1089\/ars.2012.4795","volume":"18","author":"M \u0160t\u011brba","year":"2013","unstructured":"\u0160t\u011brba M, Popelov\u00e1 O, V\u00e1vrov\u00e1 A, Jirkovsk\u00fd E, Kova\u0159\u00edkov\u00e1 P, Ger\u0161l V, \u0160im\u016fnek T (2013) Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 18:899\u2013929. \nhttps:\/\/doi.org\/10.1089\/ars.2012.4795","journal-title":"Antioxid Redox Signal"},{"key":"9820_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1089\/ars.2007.1596","volume":"9","author":"W Malorni","year":"2007","unstructured":"Malorni W, Campesi I, Straface E, Vella S, Franconi F (2007) Redox features of the cell: a gender perspective. Antioxid Redox Signal 9:1779\u20131801","journal-title":"Antioxid Redox Signal"},{"key":"9820_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117047","volume":"10","author":"V Vijay","year":"2015","unstructured":"Vijay V, Han T, Moland CL, Kwekel JC, Fuscoe JC, Desai VG (2015) Sexual dimorphism in the expression of mitochondria-related genes in rat heart at different ages. PLoS One 10:e0117047","journal-title":"PLoS One"},{"key":"9820_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00685716","volume":"27","author":"JM Jacquet","year":"1990","unstructured":"Jacquet JM, Bressolle F, Galtier M et al (1990) Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27:219\u2013225","journal-title":"Cancer Chemother Pharmacol"},{"key":"9820_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/BF00685796","volume":"36","author":"NA Dobbs","year":"1995","unstructured":"Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD (1995) Gender affects the doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36:473\u2013476","journal-title":"Cancer Chemother Pharmacol"},{"key":"9820_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF00686009","volume":"29","author":"JR Wade","year":"1992","unstructured":"Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B (1992) Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 29:391\u2013395","journal-title":"Cancer Chemother Pharmacol"},{"key":"9820_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/sj.bjc.6690019","volume":"79","author":"J van Asperen","year":"1999","unstructured":"van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH (1999) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79:108\u2013113","journal-title":"Br J Cancer"},{"key":"9820_CR29","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","volume":"332","author":"SE Lipshultz","year":"1995","unstructured":"Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738\u20131743","journal-title":"N Engl J Med"},{"key":"9820_CR30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","volume":"11","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950\u2013961","journal-title":"Lancet Oncol"},{"key":"9820_CR31","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","volume":"15","author":"JP Krischer","year":"1997","unstructured":"Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol 15:1544\u20131552","journal-title":"J Clin Oncol"},{"key":"9820_CR32","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","volume":"22","author":"O Hequet","year":"2004","unstructured":"Hequet O, Le QH, Moullet I et al (2004) Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864\u20131871","journal-title":"J Clin Oncol"},{"key":"9820_CR33","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1080\/10428190802140873","volume":"49","author":"S Myrehaug","year":"2008","unstructured":"Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, Sun A, Hodgson DC (2008) Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49:1486\u20131493","journal-title":"Leuk Lymphoma"},{"key":"9820_CR34","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood-2010-01-263764","volume":"116","author":"S Myrehaug","year":"2010","unstructured":"Myrehaug S, Pintilie M, Yun L, Crump M, Tsang RW, Meyer RM, Sussman J, Yu E, Hodgson DC (2010) A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 116:2237\u20132240","journal-title":"Blood"},{"key":"9820_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10549-015-3454-8","volume":"152","author":"MEV Caram","year":"2015","unstructured":"Caram MEV, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, van Poznak C, Cooney KA, Hertz DL, Banerjee M, Griggs JJ (2015) Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Res Treat 152:163\u2013172","journal-title":"Breast Cancer Res Treat"},{"key":"9820_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10815-012-9787-x","volume":"29","author":"KT Schmidt","year":"2012","unstructured":"Schmidt KT, Andersen CY (2012) ISFP Practice Committee. Recommendations for fertility preservation in patients with lymphomas. J Assist Reprod Genet 29:473\u2013477. \nhttps:\/\/doi.org\/10.1007\/s10815-012-9787-x","journal-title":"J Assist Reprod Genet"},{"issue":"19","key":"9820_CR37","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(19):3159\u20133165","journal-title":"J Clin Oncol"},{"key":"9820_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.biocel.2013.11.011","volume":"46","author":"M Pupo","year":"2014","unstructured":"Pupo M, Pisano A, Abonante S, Maggiolini M, Musti AM (2014) GPER activates Notch signaling in breast cancer cells and cancer-associated fibroblasts (CAFs). Int J Biochem Cell Biol 46:56\u201367. \nhttps:\/\/doi.org\/10.1016\/j.biocel.2013.11.011","journal-title":"Int J Biochem Cell Biol"},{"issue":"7","key":"9820_CR39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/carcin\/bgw048","volume":"37","author":"K Lubecka","year":"2016","unstructured":"Lubecka K, Kurzava L, Flower K, Buvala H, Zhang H, Teegarden D, Camarillo I, Suderman M, Kuang S, Andrisani O, Flanagan JM, Stefanska B (2016) Stilbenoids remodel the DNA methylation patterns in breast cancer cells and inhibit oncogenic NOTCH signaling through epigenetic regulation of MAML2 transcriptional activity. Carcinogenesis. 37(7):656\u2013668. \nhttps:\/\/doi.org\/10.1093\/carcin\/bgw048","journal-title":"Carcinogenesis."},{"key":"9820_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-015-2786-8","volume":"76","author":"Y Gonzalez","year":"2015","unstructured":"Gonzalez Y, Pokrzywinski KL, Rosen ET, Mog S, Aryal B, Chehab LM, Vijay V, Moland CL, Desai VG, Dickey JS, Rao VA (2015) Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to doxorubicin in tumor-bearing spontaneously hypertensive rats. Cancer Chemother Pharmacol 76:447\u2013459","journal-title":"Cancer Chemother Pharmacol"},{"key":"9820_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2459\/JCM.0000000000000667","volume":"19","author":"C Cadeddu Dessalvi","year":"2018","unstructured":"Cadeddu Dessalvi C, Deidda M, Mele D et al (2018) Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. J Cardiovasc Med (Hagerstown) 19:315\u2013323. \nhttps:\/\/doi.org\/10.2459\/JCM.0000000000000667","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"2","key":"9820_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0735-1097(02)02696-7","volume":"41","author":"FA Masoudi","year":"2003","unstructured":"Masoudi FA, Havranek EP, Smith G, Fish RH, Steiner JF, Ordin DL, Krumholz HM (2003) Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 41(2):217\u2013223","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"9820_CR43","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ejhf.67","volume":"16","author":"M Gori","year":"2014","unstructured":"Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJ (2014) Solomon SD; PARAMOUNT Investigators. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail 16(5):535\u2013542","journal-title":"Eur J Heart Fail"},{"key":"9820_CR44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalh\u00e3es A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911\u2013939","journal-title":"J Am Soc Echocardiogr"},{"issue":"1\u201339","key":"9820_CR45","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1\u201339):e14","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"9820_CR46","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/HYPERTENSIONAHA.107.107474","volume":"51","author":"E Gerdts","year":"2008","unstructured":"Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K, Devereux RB (2008) Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 51(4):1109\u20131114","journal-title":"Hypertension."},{"issue":"8","key":"9820_CR47","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jacc.2017.06.046","volume":"70","author":"TM Stokke","year":"2017","unstructured":"Stokke TM, Hasselberg NE, Smedsrud MK, Sarvari SI, Haugaa KH, Smiseth OA, Edvardsen T, Remme EW (2017) Geometry as a confounder when assessing ventricular systolic function: comparison between ejection fraction and strain. J Am Coll Cardiol 70(8):942\u2013954","journal-title":"J Am Coll Cardiol"},{"key":"9820_CR48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijcard.2005.07.029","volume":"111","author":"M Civelli","year":"2006","unstructured":"Civelli M, Cardinale D, Martinoni A, Lamantia G, Colombo N, Colombo A, Gandini S, Martinelli G, Fiorentini C, Cipolla CM (2006) Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 111:120\u2013126","journal-title":"Int J Cardiol"},{"issue":"4","key":"9820_CR49","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1525-2167(03)00017-9","volume":"4","author":"M Bountioukos","year":"2003","unstructured":"Bountioukos M, Doorduijn JK, Roelandt JR, Vourvouri EC, Bax JJ, Schinkel AF, Kertai MD, Sonneveld P, Poldermans D (2003) Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. Eur J Echocardiogr 4(4):300\u2013305","journal-title":"Eur J Echocardiogr"},{"key":"9820_CR50","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/0002-9149(83)90364-8","volume":"51","author":"JM Isner","year":"1983","unstructured":"Isner JM, Ferrans VJ, Cohen SR, Witkind BG, Virmani R, Gottdiener JS, Beck JR, Roberts WC (1983) Clinical and morphologic cardiac findings after anthracycline chemother- apy. Analysis of 64 patients at necropsy. Am J Cardiol 51:1167\u20131174","journal-title":"Am J Cardiol"},{"issue":"16","key":"9820_CR51","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ejca.2011.05.023","volume":"47","author":"CA Brouwer","year":"2011","unstructured":"Brouwer CA, Postma A, Vonk JM, Zwart N, van den Berg MP, Bink-Boelkens MT, Dolsma WV, Smit AJ, de Vries EG, Tissing WJ, Gietema JA (2011) Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. Eur J Cancer 47(16):2453\u20132462","journal-title":"Eur J Cancer"},{"issue":"4","key":"9820_CR52","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jjcc.2016.12.015","volume":"70","author":"H Okuma","year":"2017","unstructured":"Okuma H, Noto N, Tanikawa S, Kanezawa K, Hirai M, Shimozawa K, Yagasaki H, Shichino H, Takahashi S (2017) Impact of persistent left ventricular regional wall motion abnormalities in childhood cancer survivors after anthracycline therapy: assessment of global left ventricular myocardial performance by 3D speckle-tracking echocardiography. J Cardiol 70(4):396\u2013401","journal-title":"J Cardiol"},{"key":"9820_CR53","doi-asserted-by":"publisher","first-page":"8979407","DOI":"10.1155\/2018\/8979407","volume":"2018","author":"C Zito","year":"2018","unstructured":"Zito C, Longobardo L, Citro R, Galderisi M, Oreto L, Carerj ML, Manganaro R, Cusm\u00e0-Piccione M, Todaro MC, Di Bella G, Imbalzano E, Khandheria BK, Carerj S (2018) Ten years of 2D longitudinal strain for early myocardial dysfunction detection: a clinical overview. Biomed Res Int 2018:8979407","journal-title":"Biomed Res Int"},{"issue":"8","key":"9820_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ehjci\/jex140","volume":"18","author":"T Sugimoto","year":"2017","unstructured":"Sugimoto T, Dulgheru R, Bernard A, Ilardi F, Contu L, Addetia K, Caballero L, Akhaladze N, Athanassopoulos GD, Barone D, Baroni M, Cardim N, Hagendorff A, Hristova K, Lopez T, de la Morena G, Popescu BA, Moonen M, Penicka M, Ozyigit T, Rodrigo Carbonero JD, van de Veire N, von Bardeleben RS, Vinereanu D, Zamorano JL, Go YY, Rosca M, Calin A, Magne J, Cosyns B, Marchetta S, Donal E, Habib G, Galderisi M, Badano LP, Lang RM, Lancellotti P (2017) Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study. Eur Heart J Cardiovasc Imaging 18(8):833\u2013840","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"9820_CR55","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.recesp.2013.12.011","volume":"67","author":"G Kocabay","year":"2014","unstructured":"Kocabay G, Muraru D, Peluso D, Cucchini U, Mihaila S, Padayattil-Jose S, Gentian D, Iliceto S, Vinereanu D, Badano LP (2014) Normal left ventricular mechanics by two-dimensional speckle-tracking echocardiography. Reference values in healthy adults. Rev Esp Cardiol (Engl Ed) 67:651\u2013658","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"9820_CR56","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1253\/circj.CJ-12-0264","volume":"76","author":"K Takigiku","year":"2012","unstructured":"Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N, Tanabe K, Nakatani S, on behalf of the JUSTICE investigators (2012) Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study. Circ J 76:2623\u20132632","journal-title":"Circ J"},{"issue":"1","key":"9820_CR57","first-page":"50","volume":"112","author":"MVL Barros","year":"2019","unstructured":"Barros MVL, Macedo AVS, Sarvari SI, Faleiros MH, Felipe PT, Silva JLP, Edvardsen T (2019) Left ventricular regional wall motion abnormality is a strong predictor of cardiotoxicity in breast cancer patients undergoing chemotherapy. Arq Bras Cardiol 112(1):50\u201356","journal-title":"Arq Bras Cardiol"},{"issue":"Suppl 1","key":"9820_CR58","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.2459\/JCM.0000000000000374","volume":"17","author":"C Zito","year":"2016","unstructured":"Zito C, Longobardo L, Cadeddu C, Monte I, Novo G, Dell'Oglio S, Pepe A, Madonna R, Tocchetti CG, Mele D (2016) Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: role of echocardiography. J Cardiovasc Med (Hagerstown) 17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection):e35\u2013e44","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"9820_CR59","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/jmri.25450","volume":"45","author":"GD Aquaro","year":"2016","unstructured":"Aquaro GD, Camastra G, Monti L et al (2016) Reference values of cardiac volumes, dimensions, and new functional parameters by MR: a multicenter, multivendor study. J Magn Reson Imaging 45:1055\u20131067","journal-title":"J Magn Reson Imaging"},{"key":"9820_CR60","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCIMAGING.114.002217","volume":"7","author":"JH Jordan","year":"2014","unstructured":"Jordan JH, D'Agostino RB Jr, Hamilton CA et al (2014) Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging 7:872\u2013879","journal-title":"Circ Cardiovasc Imaging"},{"key":"9820_CR61","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jacc.2013.01.019","volume":"61","author":"K Ylanen","year":"2013","unstructured":"Ylanen K, Poutanen T, Savikurki-Heikkila P, Rinta-Kiikka I, Eerola A, Vettenranta K (2013) Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 61:1539\u20131547","journal-title":"J Am Coll Cardiol"},{"key":"9820_CR62","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCIMAGING.113.000798","volume":"6","author":"OH Toro-Salazar","year":"2013","unstructured":"Toro-Salazar OH, Gillan E, O'Loughlin MT et al (2013) Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 6:873\u2013880","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"9820_CR63","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/hrt.2010.199760","volume":"97","author":"PR Mitoff","year":"2011","unstructured":"Mitoff PR, Gam D, Ivanov J, Al-hesayen A, Azevedo ER, Newton GE, Parker JD, Mak S (2011) Cardiac-specific sympathetic activation in men and women with and without heart failure. Heart. 97(5):382\u2013387. \nhttps:\/\/doi.org\/10.1136\/hrt.2010.199760","journal-title":"Heart."},{"issue":"3","key":"9820_CR64","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ahj.2007.04.047","volume":"154","author":"PR Mitoff","year":"2007","unstructured":"Mitoff PR, Al-Hesayen A, Azevedo E, Newton GE, Mak S (2007) Sex differences in basal hemodynamics and left ventricular function in humans with and without heart failure. Am Heart J 154(3):575\u2013580","journal-title":"Am Heart J"},{"key":"9820_CR65","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","volume":"30","author":"GT Armstrong","year":"2012","unstructured":"Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD (2012) Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 30:2876\u20132884","journal-title":"J Clin Oncol"},{"key":"9820_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1532-429X-15-48","volume":"15","author":"EB Tham","year":"2013","unstructured":"Tham EB, Haykowsky MJ, Chow K, Spavor M, Kaneko S, Khoo NS, Pagano JJ, Mackie AS, Thompson RB (2013) Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson 15:48","journal-title":"J Cardiovasc Magn Reson"},{"key":"9820_CR67","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/heartjnl-2015-307894","volume":"102","author":"AF Yu","year":"2016","unstructured":"Yu AF, Ky B (2016) Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart. 102:425\u2013430. \nhttps:\/\/doi.org\/10.1136\/heartjnl-2015-307894","journal-title":"Heart."},{"key":"9820_CR68","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrcardio.2015.105","volume":"12","author":"LB Daniels","year":"2015","unstructured":"Daniels LB, Maisel AS (2015) Cardiovascular biomarkers and sex: the case for women. Nat Rev Cardiol 12:588\u2013596. \nhttps:\/\/doi.org\/10.1038\/nrcardio.2015.105","journal-title":"Nat Rev Cardiol"},{"key":"9820_CR69","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ejhf.1209","volume":"20","author":"N Suthahar","year":"2018","unstructured":"Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA (2018) Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. Eur J Heart Fail 20:1205\u20131214. \nhttps:\/\/doi.org\/10.1002\/ejhf.1209","journal-title":"Eur J Heart Fail"},{"key":"9820_CR70","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749\u20132754","journal-title":"Circulation"},{"key":"9820_CR71","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00277-003-0615-3","volume":"82","author":"HW Auner","year":"2003","unstructured":"Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82:218\u2013222","journal-title":"Ann Hematol"},{"key":"9820_CR72","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","volume":"18","author":"BE Levis","year":"2017","unstructured":"Levis BE, Binkley PF, Shapiro CL (2017) Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol 18:e445\u2013e456","journal-title":"Lancet Oncol"},{"key":"9820_CR73","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijcard.2009.09.564","volume":"148","author":"M Feola","year":"2011","unstructured":"Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, Albrile F, Bobbio M, Merlano M (2011) Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 148:194\u2013198","journal-title":"Int J Cardiol"},{"key":"9820_CR74","first-page":"e67","volume":"166","author":"G Pistillucci","year":"2015","unstructured":"Pistillucci G, Ciorra AA, Sciacca V, Raponi M, Rossi R, Veltri E (2015) Troponin I and B-type natriuretic peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab. Clin Ther 166:e67\u2013e71","journal-title":"Clin Ther"},{"key":"9820_CR75","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63:809\u2013816","journal-title":"J Am Coll Cardiol"},{"key":"9820_CR76","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/cvr\/cvu225","volume":"104","author":"S Lecour","year":"2014","unstructured":"Lecour S, B\u00f8tker HE, Condorelli G et al (2014) ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res 104:399\u2013411. \nhttps:\/\/doi.org\/10.1093\/cvr\/cvu225","journal-title":"Cardiovasc Res"},{"key":"9820_CR77","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1089\/ars.2010.3360","volume":"14","author":"DJ Hausenloy","year":"2011","unstructured":"Hausenloy DJ, Lecour S, Yellon DM (2011) Reperfusion injury salvage kinase andsurvivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 14:893\u2013907. \nhttps:\/\/doi.org\/10.1089\/ars.2010.3360","journal-title":"Antioxid Redox Signal"},{"key":"9820_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/cvr\/cvt004","volume":"98","author":"DJ Hausenloy","year":"2013","unstructured":"Hausenloy DJ, Botker HE, Condorelli G et al (2013) Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the heart of the European Society of Cardiology. Cardiovasc Res 98:7\u201327. \nhttps:\/\/doi.org\/10.1093\/cvr\/cvt004","journal-title":"Cardiovasc Res"},{"key":"9820_CR79","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2015.04.232","volume":"191","author":"R Madonna","year":"2015","unstructured":"Madonna R, Cadeddu C, Deidda M, Giricz Z, Madeddu C, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Varga ZV, Zito C, Geng YJ, Mercuro G, Ferdinandy P (2015) Cardioprotection by gene therapy: a review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. Int J Cardiol 191:203\u2013210. \nhttps:\/\/doi.org\/10.1016\/j.ijcard.2015.04.232","journal-title":"Int J Cardiol"},{"issue":"3","key":"9820_CR80","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.tcm.2010.05.001","volume":"20","author":"AM Deschamps","year":"2010","unstructured":"Deschamps AM, Murphy E, Sun J (2010) Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc Med 20(3):73\u201378. \nhttps:\/\/doi.org\/10.1016\/j.tcm.2010.05.001","journal-title":"Trends Cardiovasc Med"},{"issue":"10","key":"9820_CR81","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1007\/s11064-019-02769-6","volume":"44","author":"Jasmine A. Fels","year":"2019","unstructured":"Fels JA, Manfredi G (2019) Sex differences in ischemia\/reperfusion injury: the role of mitochondrial permeability transition. Neurochem Res. \nhttps:\/\/doi.org\/10.1007\/s11064-019-02769-6","journal-title":"Neurochemical Research"},{"issue":"3","key":"9820_CR82","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cardiores.2007.03.025","volume":"75","author":"E Murphy","year":"2007","unstructured":"Murphy E, Steenbergen C (2007) Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc Res 75(3):478\u2013486","journal-title":"Cardiovasc Res"},{"issue":"9","key":"9820_CR83","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1139\/cjpp-2019-0060","volume":"97","author":"B. Ostadal","year":"2019","unstructured":"Ostadal B, Drahota Z, Houstek J, Milerova M, Ostadalova I, Hlavackova M, Kolar F (2019) Developmental and sex differences in cardiac tolerance to ischemia\/reperfusion injury: the role of mitochondria. Can J Physiol Pharmacol:1\u20137. \nhttps:\/\/doi.org\/10.1139\/cjpp-2019-0060","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"issue":"3","key":"9820_CR84","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bph.12270","volume":"171","author":"B Ostadal","year":"2014","unstructured":"Ostadal B, Ostadal P (2014) Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. Br J Pharmacol 171(3):541\u2013554. \nhttps:\/\/doi.org\/10.1111\/bph.12270","journal-title":"Br J Pharmacol"},{"issue":"4","key":"9820_CR85","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00395-008-0762-8","volume":"104","author":"C Penna","year":"2009","unstructured":"Penna C, Tullio F, Merlino A, Moro F, Raimondo S, Rastaldo R, Perrelli MG, Mancardi D, Pagliaro P (2009) Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol 104(4):390\u2013402. \nhttps:\/\/doi.org\/10.1007\/s00395-008-0762-8","journal-title":"Basic Res Cardiol"},{"key":"9820_CR86","doi-asserted-by":"publisher","unstructured":"Rocca C, Femmin\u00f2 S, Aquila G, Granieri MC, De Francesco EM, Pasqua T, Rigiracciolo DC, Fortini F, Cerra MC, Maggiolini M, Pagliaro P, Rizzo P, Angelone T, Penna C (2018) Notch1 mediates preconditioning protection induced by GPER in normotensive and hypertensive female rat hearts. Front Physiol 9:521. \nhttps:\/\/doi.org\/10.3389\/fphys.2018.00521.eCollection2018","DOI":"10.3389\/fphys.2018.00521.eCollection2018"},{"key":"9820_CR87","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","volume":"340","author":"ME Mendelsohn","year":"1999","unstructured":"Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801\u20131811","journal-title":"N Engl J Med"},{"key":"9820_CR88","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.yjmcc.2011.08.021","volume":"52","author":"E Murphy","year":"2012","unstructured":"Murphy E, Kohr M, Sun J, Nguyen T, Steenbergen C (2012) S-nitrosylation: a radical way to protect the heart. J Mol Cell Cardiol 52:568\u2013577. \nhttps:\/\/doi.org\/10.1016\/j.yjmcc.2011.08.021","journal-title":"J Mol Cell Cardiol"},{"key":"9820_CR89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.yjmcc.2017.08.012","volume":"112","author":"LA Bienvenu","year":"2017","unstructured":"Bienvenu LA, Morgan J, Reichelt ME, Delbridge LMD, Young MJ (2017) Chronic in vivo nitric oxide deficiency impairs cardiac functional recovery after ischemia in female (but not male) mice. J Mol Cell Cardiol 112:8\u201315. \nhttps:\/\/doi.org\/10.1016\/j.yjmcc.2017.08.012","journal-title":"J Mol Cell Cardiol"},{"key":"9820_CR90","doi-asserted-by":"publisher","first-page":"H505","DOI":"10.1152\/ajpheart.00681.2015","volume":"310","author":"Q Shao","year":"2016","unstructured":"Shao Q, Fallica J, Casin KM, Murphy E, Steenbergen C, Kohr MJ (2016) Characterization of the sex-dependent myocardial S-nitrosothiol proteome. Am J Physiol Heart Circ Physiol 310:H505\u2013H515. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00681.2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9820_CR91","doi-asserted-by":"publisher","first-page":"H825","DOI":"10.1152\/ajpheart.00660.2013","volume":"306","author":"G Tong","year":"2014","unstructured":"Tong G, Aponte AM, Kohr MJ, Steenbergen C, Murphy E, Sun J (2014) Postconditioning leads to an increase in protein S-nitrosylation. Am J Physiol Heart Circ Physiol 306:H825\u2013H832","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9820_CR92","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/1535370214522935","volume":"239","author":"C Penna","year":"2014","unstructured":"Penna C, Angotti C, Pagliaro P (2014) Protein S-nitrosylation in preconditioning and postconditioning. ExpBiol Med (Maywood) 239:647\u2013662","journal-title":"ExpBiol Med (Maywood)"},{"key":"9820_CR93","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/HYPERTENSIONAHA.110.150839","volume":"55","author":"F Wang","year":"2010","unstructured":"Wang F, He Q, Sun Y, Dai X, Yang XP (2010) Female adult mouse cardiomyocytes are protected against oxidative stress. Hypertension 55:1172\u20131178","journal-title":"Hypertension"},{"key":"9820_CR94","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-10-3145","volume":"71","author":"Cosper and Leinwand","year":"2011","unstructured":"Cosper and Leinwand (2011) Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res 71:1710\u20131720","journal-title":"Cancer Res"},{"key":"9820_CR95","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.114.001180","volume":"8","author":"M Moulin","year":"2015","unstructured":"Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, Lefebvre F, Gresikova M, Solgadi A, Veksler V, Garnier A, Ventura-Clapier R (2015) Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail 8:98\u2013108","journal-title":"Circ Heart Fail"},{"key":"9820_CR96","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13293-015-0039-5","volume":"6","author":"M Moulin","year":"2015","unstructured":"Moulin M, Solgadi A, Veksler V, Garnier A, Ventura-Clapier R, Chaminade P (2015) Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment. Biol Sex Differ 6:20","journal-title":"Biol Sex Differ"},{"key":"9820_CR97","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/jcp.25585","volume":"232","author":"EM De Francesco","year":"2017","unstructured":"De Francesco EM, Rocca C, Scavello F et al (2017) Protective role of GPER agonist G-1 on cardiotoxicity induced by doxorubicin. J Cell Physiol 232:1640\u20131649. \nhttps:\/\/doi.org\/10.1002\/jcp.25585","journal-title":"J Cell Physiol"},{"key":"9820_CR98","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF00364850","volume":"61","author":"RH Julicher","year":"1988","unstructured":"Julicher RH, Sterrenberg L, Haenen GR, Bast A, Noordhoek J (1988) The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. Arch Toxicol 61:275\u2013281","journal-title":"Arch Toxicol"},{"key":"9820_CR99","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/0192623313482778","volume":"42","author":"J Zhang","year":"2014","unstructured":"Zhang J, Knapton A, Lipshultz SE, Cochran TR, Hiraragi H, Herman EH (2014) Sex-related differences in mast cell activity and doxorubicin toxicity: a study in spontaneously hypertensive rats. Toxicol Pathol 42:361\u2013375","journal-title":"Toxicol Pathol"},{"key":"9820_CR100","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejphar.2005.08.056","volume":"523","author":"JR Munoz-Castaneda","year":"2005","unstructured":"Munoz-Castaneda JR, Montilla P, Munoz MC, Bujalance I, Muntane J, Tunez I (2005) Effect of 17-beta-estradiol administration during adriamycin-induced cardiomyopathy in ovariectomized rat. Eur J Pharmacol 523:86\u201392","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"9820_CR101","doi-asserted-by":"publisher","first-page":"pii: e002383","DOI":"10.1161\/JAHA.115.002383","volume":"5","author":"P Altieri","year":"2016","unstructured":"Altieri P, Barisione C, Lazzarini E et al (2016) Testosterone antagonizes doxorubicin-induced senescence of cardiomyocytes. J Am Heart Assoc 5(1):pii: e002383","journal-title":"J Am Heart Assoc"},{"key":"9820_CR102","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10741-015-9497-4","volume":"20","author":"R Madonna","year":"2015","unstructured":"Madonna R, Cadeddu C, Deidda M, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Zito C, Mercuro G (2015) Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a position paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev 20:621\u2013631. \nhttps:\/\/doi.org\/10.1007\/s10741-015-9497-4","journal-title":"Heart Fail Rev"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09820-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09820-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09820-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T23:10:02Z","timestamp":1593299402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09820-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,29]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["9820"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09820-2","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,29]]},"assertion":[{"value":"29 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Carlo Gabriele Tocchetti received speaking fees from Alere; Rudolf A de Boer: the UMCG, which employs RAdB, has received research grants and\/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Roche, Trevena, and ThermoFisher GmbH. RAdB is a minority shareholder of scPharmaceuticals, Inc. RAdB received personal fees from MandalMed Inc., AstraZeneca, Novartis, Servier, and Vifor. Alexander R. Lyon has received speaker, advisory board or consultancy fees, and\/or research grants from Pfizer, Novartis, Servier, Amgen, Clinigen Group, Takeda, Roche, Eisai Ltd., Eli Lily, and Boehringer Ingelheim. Javid Moslehi has served as a consultant\/advisor for Novartis, Pfizer, Bristol-Myers Squibb, Takeda\/Millennium, Ariad, Acceleron, Vertex, Incyte, Rgenix, Verastem, Pharmacyclics, StemCentRx, Heat Biologics, Daiichi-Sankyo, and Regeneron. All other authors have no conflicts of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}